Keyphrases
Apoptosis
11%
Cancer Cell Proliferation
10%
Cancer Therapy
19%
Chronic Inflammatory Diseases
15%
Clinical Trials
11%
Cluster of Differentiation 44 (CD44)
12%
Colitis
17%
Colon Cancer
9%
Colorectal Cancer
36%
COVID-19
27%
Crohn's Disease
100%
Crohn's Disease Activity
11%
Crypt Fission
9%
Cyclooxygenase-2
9%
Dextran Sulfate Sodium
11%
Diarrhea
11%
Disease Activity
10%
Enterotoxigenic Escherichia Coli
22%
Gastrointestinal Diseases
23%
Gastrointestinal Tract
10%
Hyaluronic Acid
16%
Indoleamine 2,3-dioxygenase 1 (IDO1)
41%
Inflammation
19%
Inflammatory Bowel Disease
95%
Innate Immune Response
13%
Intestinal Epithelial Cells
23%
Intestinal Epithelium
13%
Intestinal Growth
10%
Irritable Bowel Syndrome
15%
Kynurenine Pathway
11%
Lgr5+
13%
Magnetic Resonance Enterography
10%
Methionine Oxidation
13%
Microbiome
9%
Mucositis
10%
Non-alcoholic Fatty Liver Disease (NAFLD)
18%
Radiation Damage
14%
Radioprotection
9%
Sleep Disturbance
9%
Small Intestine
27%
Therapeutic Target
11%
Tofacitinib
15%
Toll-like Receptor 4 (TLR4)
14%
Training Challenges
9%
Tryptophan
11%
Tryptophan Metabolism
11%
Ulcerative Colitis
30%
United States
10%
Vaccination
13%
Vedolizumab
22%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Biological Marker
17%
Biological Product
13%
Carcinogenesis
17%
Catenin
6%
Chemotherapy
6%
Clinical Trial
14%
Clostridium Difficile Infection
6%
Cohort Study
9%
Colitis
20%
Colon Carcinoma
13%
Colorectal Carcinoma
18%
Crohn's Disease
45%
Cyclooxygenase 2
6%
Dextran Sulfate
7%
Disease Activity
8%
Disease Course
6%
Diseases
39%
Enteritis
7%
Gastrointestinal Symptom
9%
Hyaluronic Acid
9%
Immunogenicity
9%
Indoleamine 2,3 Dioxygenase
25%
Infection
17%
Inflammation
13%
Inflammatory Bowel Disease
53%
Inflammatory Disease
14%
Intestine Flora
7%
Irritable Colon
6%
Janus Kinase Inhibitor
7%
Kynurenine
13%
Lactobacillus
6%
Lactobacillus rhamnosus
9%
Malignant Neoplasm
32%
Messenger RNA
11%
Microbiome
10%
Microflora
8%
Mucosa Inflammation
10%
Neoplasm
7%
Pyroptosis
6%
Radiation Injury
16%
Remission
9%
SARS Coronavirus
16%
Sleep Disorder
9%
Tofacitinib
15%
Toll Like Receptor 4
9%
Tryptophan
11%
Tumor Necrosis Factor Inhibitor
7%
Ulcerative Colitis
26%
Vedolizumab
17%
Medicine and Dentistry
Bariatric Surgery
9%
Biological Marker
8%
Cancer Therapy
14%
Cell Proliferation
11%
Clinical Trial
8%
Colitis
10%
Colorectal Carcinoma
17%
COVID-19
7%
Crohn's Disease
40%
Cyclooxygenase 2
6%
Dextran Sulfate
6%
Diarrhea
10%
Disease Activity
13%
Disease Course
10%
Diseases
33%
Enteritis
6%
Enterotoxigenic Escherichia Coli
9%
Epithelial Cell
10%
Gastrointestinal Distress
13%
Gut
8%
Immunotherapy
6%
Indoleamine 2,3 Dioxygenase
13%
Infection
6%
Inflammatory Bowel Disease
73%
Intestinal Epithelium
6%
Irritable Bowel Syndrome
9%
Magnetic Resonance Enterography
10%
Microbiome
6%
Mucositis
9%
Mucus
6%
Myofibroblast
6%
Nonalcoholic Fatty Liver
13%
Organismal Interaction
6%
Patient with Crohn's Disease
10%
Patient with Inflammatory Bowel Disease
8%
Prevalence
6%
Probiotics
25%
Programmed Cell Death
7%
Proton Nuclear Magnetic Resonance
6%
Radiation Injury
9%
Radiation Therapy
11%
Receptor
6%
Rectum Cancer
9%
Restylane
13%
Stem Cell
16%
Systematic Review
6%
TNF Inhibitor
6%
Toll Like Receptor 4
14%
Ulcerative Colitis
20%
Vedolizumab
13%